Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pharmaceutical Vaneck ETF (PPH)

Pharmaceutical Vaneck ETF (PPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Van Eck Associates
  • Assets Under Management 171,813,100
  • Market Capitalization, $K 171,813
  • Shares Outstanding, K 2,888
  • 60-Month Beta 0.96
  • Price/Earnings ttm 25.27
  • Annual Dividend & Yield 1.17 (1.95%)
  • Most Recent Dividend 0.292 on 10/01/19
  • Management Fee 0.36%
  • Sectors:

    ETFs - Healthcare

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.92 +7.58%
on 10/14/19
60.39 -0.38%
on 11/12/19
+4.12 (+7.35%)
since 10/11/19
3-Month
54.48 +10.43%
on 10/03/19
60.39 -0.38%
on 11/12/19
+3.42 (+6.03%)
since 08/12/19
52-Week
52.39 +14.83%
on 12/26/18
63.25 -4.89%
on 11/13/18
-2.56 (-4.08%)
since 11/12/18

Most Recent Stories

More News
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 60.16 (+1.19%)
XPH : 38.18 (-1.01%)
PJP : 60.19 (+0.18%)
ALXN : 109.44 (+0.39%)
BIIB : 291.40 (-0.93%)
ACHN : 6.34 (-0.16%)
DERM : 8.09 (+0.56%)
GLYC : 5.96 (+1.02%)
RIGL : 2.27 (-1.73%)
IRWD : 11.35 (+2.16%)
Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

XPH : 38.18 (-1.01%)
PJP : 60.19 (+0.18%)
PPH : 60.16 (+1.19%)
IHE : 143.98 (-0.19%)
FTXH : 21.25 (+0.37%)
Announcing VanEck Vectors ETFs' September 2019 Distributions

VanEck announced today its distributions per share for its VanEck Vectors(R) exchange-traded funds.

PPH : 60.16 (+1.19%)
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

PJP : 60.19 (+0.18%)
XPH : 38.18 (-1.01%)
PPH : 60.16 (+1.19%)
IHE : 143.98 (-0.19%)
FTXH : 21.25 (+0.37%)
Announcing VanEck Vectors ETFs' June 2019 Distributions

VanEck announced today its distributions per share for its VanEck Vectors(R) exchange-traded funds.

PPH : 60.16 (+1.19%)
AbbVie to Buy Allergan: Prescribed ETFs

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

BMY : 58.39 (+0.41%)
AGN : 181.96 (+0.21%)
ABBV : 86.44 (+0.91%)
BBH : 131.84 (+0.68%)
PPH : 60.16 (+1.19%)
XPH : 38.18 (-1.01%)
IHE : 143.98 (-0.19%)
PJP : 60.19 (+0.18%)
CELG : 110.00 (+0.39%)
Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

XPH : 38.18 (-1.01%)
PJP : 60.19 (+0.18%)
IHE : 143.98 (-0.19%)
PPH : 60.16 (+1.19%)
FTXH : 21.25 (+0.37%)
Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

XPH : 38.18 (-1.01%)
PJP : 60.19 (+0.18%)
IHE : 143.98 (-0.19%)
PPH : 60.16 (+1.19%)
FTXH : 21.25 (+0.37%)
Announcing VanEck Vectors ETFs' March 2019 Distributions

VanEck announced today its distributions per share for its VanEck Vectors(R) exchange-traded funds.

PPH : 60.16 (+1.19%)
A Look at Pharma ETFs Post Q4 Results

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month.

IHE : 143.98 (-0.19%)
PPH : 60.16 (+1.19%)
PJP : 60.19 (+0.18%)
XPH : 38.18 (-1.01%)
FTXH : 21.25 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade PPH with:

Fund Summary

The VanEck Vectors Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical...

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

2nd Resistance Point 60.73
1st Resistance Point 60.45
Last Price 60.16
1st Support Level 59.82
2nd Support Level 59.47

See More

52-Week High 63.25
Last Price 60.16
Fibonacci 61.8% 59.10
Fibonacci 50% 57.82
Fibonacci 38.2% 56.54
52-Week Low 52.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar